Search | Médecins Sans Frontières Access Campaign

About us
About the Access Campaign

Some of our 2023 plans

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

Pandemic prevention, preparedness and response

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

A Fair Shot

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)

Recent campaigns

Time for $5

No Patents in a Pandemic

Share the Tech - Save Lives
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action!

4 results found
There are 10 active filters
Clear all filters
HIV/AIDS
Novartis
antiretroviral medicines
FDCs
vaccines

4 results found

Statement |

27 June 2013

Oral Testimony at US Congressional Hearing: “A Tangle of Trade Barriers: How India’s Industrial Policy is Hurting U.S. Companies.”

Tags Intellectual property and trade HIV/AIDS antiretroviral medicines compulsory licencefree trade agreementuniversal access Novartis India

Photo of Manica BALASEGARAM

Feature story |

19 December 2012

Looking Ahead to 2013 with MSF's Dr Manica Balasegaram

Tags HIV/AIDSIntellectual property and tradeResearch and developmentTropical & neglected diseasesTuberculosisVaccines HIV/AIDSneglected diseasestuberculosis vaccines research and development (R&D) Novartis Novartis Drop the Case Campaign

Press release |

11 September 2012

Novartis’ six-year legal challenge against India’s pro-health patent law heads to Supreme Court

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicines Novartis Novartis Drop the Case Campaign India

Research article |

28 November 2006

Treating HIV in the developing world: getting ahead of the drug development curve

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicinesFDCstenofovir CiplaGileadMerckNovartis Novartis Drop the Case Campaign South Africa